Bone grafting material in combination with Osteogain for bone repair: a rat histomorphometric study
- 1.1k Downloads
Enamel matrix derivative (EMD) has been successfully used for the regeneration of periodontal tissues including new cementum, periodontal ligament, and alveolar bone. Combination of EMD with bone grafting materials has however generated variable clinical results. Recently, we have demonstrated that a new formulation of EMD in a liquid carrier system (Osteogain®) has improved physicochemical properties for the adsorption of EMD to a bone grafting material. The aim of the present study was to investigate the regenerative potential of Osteogain®, in combination with a bone graft, on new bone formation in a rat femur defect model.
Materials and methods
Fifty-four critically sized femur defects (3 mm in diameter) were created bilaterally in 27 rats and treated following the group allocation: (1) drilled unfilled control, (2) a natural bone mineral (NBM), and (3) NBM + Osteogain®. All defects were histologically analyzed at 2, 4, and 8 weeks after surgical intervention. Micro-CT analysis, hematoxylin and eosin (H&E) staining, and Safranin O staining were performed to quantify new bone formation.
Significantly more new bone formation was observed in defects treated with NBM + Osteogain® at both 4 and 8 weeks when compared to NBM alone and the control unfilled defects (P < 0.05). Histologically, the formation of more mature mineralized bone with the presence of osteocytes were found more commonly in defects treated with Osteogain® + NBM at 8 weeks post-healing when compared to NBM alone.
The present study demonstrate that Osteogain® in combination with a bone grafting material improves the speed and quality of new bone formation in rat osseous defects.
Future clinical research are now warranted to fully characterize the benefits of Osteogain®, a new formulation of enamel matrix proteins delivered in liquid formation when used in combination with a bone grafting material.
KeywordsEnamel matrix derivative (EMD) Emdogain Natural bone mineral BioOss Bone grafting materials
Conflict of interest
The study was funded by Straumann AG, Basel, Switzerland. The NBM bone graft was provided by Geistlich Pharma AG, Switzerland, and Osteogain® was provided by Straumann AG, Switzerland. No further conflict of interest exists.
- 3.Pietruska M, Pietruski J, Nagy K, Brecx M, Arweiler NB, Sculean A (2012) Four-year results following treatment of intrabony periodontal defects with an enamel matrix derivative alone or combined with a biphasic calcium phosphate. Clinical oral investigations 16:1191–1197. doi: 10.1007/s00784-011-0611-2 CrossRefPubMedGoogle Scholar
- 10.Guida L, Annunziata M, Belardo S, Farina R, Scabbia A, Trombelli L (2007) Effect of autogenous cortical bone particulate in conjunction with enamel matrix derivative in the treatment of periodontal intraosseous defects. J Periodontol 78:231–238. doi: 10.1902/jop.2007.060142 CrossRefPubMedGoogle Scholar
- 12.Velasquez-Plata D, Scheyer ET, Mellonig JT (2002) Clinical comparison of an enamel matrix derivative used alone or in combination with a bovine-derived xenograft for the treatment of periodontal osseous defects in humans. J Periodontol 73:433–440. doi: 10.1902/jop.2002.73.4.433 CrossRefPubMedGoogle Scholar
- 13.Lekovic V, Camargo PM, Weinlaender M, Nedic M, Aleksic Z, Kenney EB (2000) A comparison between enamel matrix proteins used alone or in combination with bovine porous bone mineral in the treatment of intrabony periodontal defects in humans. J Periodontol 71:1110–1116. doi: 10.1902/jop.2000.71.7.1110 CrossRefPubMedGoogle Scholar
- 15.Gurinsky BS, Mills MP, Mellonig JT (2004) Clinical evaluation of demineralized freeze-dried bone allograft and enamel matrix derivative versus enamel matrix derivative alone for the treatment of periodontal osseous defects in humans. J Periodontol 75:1309–1318. doi: 10.1902/jop.2004.75.10.1309 CrossRefPubMedGoogle Scholar
- 17.Miron RJ, Bosshardt DD, Buser D, Zhang Y, Tugulu S, Gemperli A, Dard M, Caluseru OM, Chandad F and Sculean A (2015) Comparison of the capacity of enamel matrix derivative-gel and enamel matrix derivative in liquid formulation to adsorb to bone grafting materials. J Periodontol:1–18. doi: 10.1902/jop.2015.140538
- 24.Wei L, Ke J, Prasadam I, Miron RJ, Lin S, Xiao Y, Chang J, Wu C and Zhang Y (2014) A comparative study of Sr-incorporated mesoporous bioactive glass scaffolds for regeneration of osteopenic bone defects. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 25:2089–2096. doi: 10.1007/s00198-014-2735-0
- 26.Miron RJ, Bosshardt DD, Hedbom E, Zhang Y, Haenni B, Buser D, Sculean A (2012) Adsorption of enamel matrix proteins to a bovine-derived bone grafting material and its regulation of cell adhesion, proliferation, and differentiation. J Periodontol 83:936–947. doi: 10.1902/jop.2011.110480 CrossRefPubMedGoogle Scholar
- 28.Scheyer ET, Velasquez-Plata D, Brunsvold MA, Lasho DJ, Mellonig JT (2002) A clinical comparison of a bovine-derived xenograft used alone and in combination with enamel matrix derivative for the treatment of periodontal osseous defects in humans. J Periodontol 73:423–432. doi: 10.1902/jop.2002.73.4.423 CrossRefPubMedGoogle Scholar
- 29.Sculean A, Chiantella GC, Windisch P, Gera I, Reich E (2002) Clinical evaluation of an enamel matrix protein derivative (Emdogain) combined with a bovine-derived xenograft (Bio-Oss) for the treatment of intrabony periodontal defects in humans. Int J Periodontics Restorative Dent 22:259–267PubMedGoogle Scholar
- 31.Boyan BD, Weesner TC, Lohmann CH, Andreacchio D, Carnes DL, Dean DD, Cochran DL, Schwartz Z (2000) Porcine fetal enamel matrix derivative enhances bone formation induced by demineralized freeze dried bone allograft in vivo. J Periodontol 71:1278–1286. doi: 10.1902/jop.2000.71.8.1278 CrossRefPubMedGoogle Scholar